Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Estramustine
Drug ID BADD_D00826
Description A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.
Indications and Usage For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate
Marketing Status approved; investigational
ATC Code L01XX11
DrugBank ID DB01196
KEGG ID D04066
MeSH ID D004961
PubChem ID 259331
TTD Drug ID D03SRY
NDC Product Code Not Available
UNII 35LT29625A
Synonyms Estramustine | Estracyt | Estramustine Phosphate Sodium | Phosphate Sodium, Estramustine | Leo-275 | Leo 275 | Leo275 | NSC-89199 | NSC 89199 | NSC89199 | Emcyt | Estramustinphosphate | Estramustin Phosphate | Phosphate, Estramustin
Chemical Information
Molecular Formula C23H31Cl2NO3
CAS Registry Number 2998-57-4
SMILES CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Alopecia23.02.02.001--
Anxiety19.06.02.002--
Cardiac arrest02.03.04.001--
Cardiac failure congestive02.05.01.002--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Congenital anomaly03.02.01.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Developmental delay19.07.05.003; 08.01.03.037--Not Available
Diarrhoea07.02.01.001--
Dry skin23.03.03.001--
Dysphonia17.02.08.004; 22.12.03.006; 19.19.03.002--
Dyspnoea02.11.05.003; 22.02.01.004--
Embolism venous24.01.01.003--Not Available
Eye pain06.08.03.002--
Flatulence07.01.04.002--
Flushing08.01.03.025; 24.03.01.002; 23.06.05.003--
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Glucose tolerance decreased13.02.02.004--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Headache17.14.01.001--
Hypercalcaemia14.04.01.003; 05.04.01.002--
Hypernatraemia14.05.04.001--
Increased tendency to bruise01.01.03.005; 24.07.06.012; 23.06.01.009--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Lacrimation increased06.08.02.004--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukopenia01.02.02.001--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages